Skip to main content
Top navigation
  • Sustainability reports
  • Focus area: Increase resource efficiency
  • Governance
  • Please fill out this field

Main navigation

    • Our offering
        • Solids & others
            • Manufacturing
                • Solids
                • Semi-solids
                • Liquids
                • Pharmaceutical packaging
                • Controlled drugs
                • High Potent
        • Sterile delivery
            • Manufacturing
                • Sterile vial filling
                • PFS and cartridges
                • Lyophilisation
                • Blow-fill-seal
                • Ampoules
            • Specialised services
                • Ophthalmics
                • Beta-lactams
                • Vaccine manufacturing
        • Advanced Bio
            • Modalities & services
                • xRNA therapies
                • Virus & viral vectors
                • Microbial & live biotherapeutic products
                • Recombinant proteins
            • Continuous manufacturing
            • Innovations & collaborations
        • Additional services
            • ReciPredict
            • Analytical services
            • Regulatory
            • Parenteral drug development
            • New product introduction
                • Technology Transfer
                • Product development
    • Resources
    • About us
        • About us
            • Our leadership
            • Why partner with us
            • Locations
        • Sustainability
            • Sustainability reports
            • Sustainability strategy
            • Net Zero commitment
            • Governance
        • News & Events
            • Press releases
            • Events
    • Careers
        • Careers
            • Who we are
            • Working with us
            • What you can do
            • Job search
    • Contact
Linkedin
Contact
Please fill out this field
No banner Image

  • Home
  • Facebook
  • Linkedin
  • Twitter
  • Email
September 09 2024
ReciBioPharm and Hongene Biotech Corporation establish a gene editing development partnership
September 04 2024
Introducing ReciPredict: Revolutionising Drug Product Development and Manufacturing
January 23 2024
Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology
September 03 2024
Recipharm completes divestment of seven sites
June 13 2024
MARBIO receives new grant funding
April 02 2024
Recipharm strengthens its competitiveness by focusing on leading, core CDMO segments
April 02 2024
Bespak confirms completion of inhaled and nasal drug delivery business separation from Recipharm
March 26 2024
Recipharm attains major sustainability milestones
March 13 2024
ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors
December 19 2023
Recipharm harmonizes its global quality operations with Veeva Vault Quality

Pagination

  • First page
  • Previous page
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Next page
  • Last page
Subscribe to

Footer Webfrom

contact form

Let’s discuss your 
next project

Share your details and start your journey with our global CDMO team.

Stay updated
https://se.linkedin.com/company/recipharm https://www.youtube.com/channel/UCr-bw7pCCkYZfeImOwTfNRg
Footer
  • Privacy policy
  • Cookies
  • Website terms
  • Sitemap
  • Cookie settings
  • Terms & conditions
  • Code of Conduct
© 2026

Recipharm AB. All rights reserved. RECIPHARM® is a registered trademark owned by Recipharm AB.

Delivered by Investisdigital [iDX]